WenTongGanPi decoction alleviates diarrhea-predominant irritable bowel syndrome by improving intestinal barrier

被引:2
|
作者
Li, Yaoguang [1 ]
Chen, Yangyang [2 ]
Liao, Zhengyue [3 ]
Liu, Yixin [3 ]
Liu, Chenhao [4 ]
Yang, Wenjing [3 ]
Bai, Jing [3 ]
Huang, Xinggui [4 ]
Hao, Yule [4 ]
Liu, Sijing [1 ,3 ]
Liu, Yi [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 611103, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611103, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chengdu 611103, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Coll Basic Med Sci, Chengdu 610075, Peoples R China
关键词
WenTongGanPi decoction; Irritable bowel syndrome; Diarrhea; MAPK signal pathway; Intestinal barrier; Gut microbiota; CHAIN FATTY-ACIDS; Q-TOF-MS/MS; METABOLITE; MICROBIOTA; MAPK;
D O I
10.1016/j.jep.2024.118544
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: WenTongGanPi Decoction (WTGPD) is a representative medical practice of the Fuyang School of Traditional Chinese Medicine (TCM), which originated from the classical Lu's Guizhi method. WTGPD places emphasis on the balance and functionality of yang qi, and is effective in treating TCM symptoms related to liver qi stagnation and spleen yang deficiency. In TCM, diarrhea-predominant irritable bowel syndrome (IBS-D) is often diagnosed as liver depression and spleen deficiency, and the use of WTGPD has shown significant therapeutic effect. However, the underlying mechanism of WTGPD treating IBS-D remains unclear. Aim of the study: To explore the effect and mechanism of WTGPD in the treatment of IBS-D. Materials and methods: An IBS-D model with liver depression and spleen deficiency was constructed by chronic immobilization stress stimulation and sennae folium aqueous gavage. The impact of WTGPD on IBS-D rats was evaluated through measurements of body weight, fecal water content, and abdominal withdrawal reflex (AWR). Intestinal permeability was assessed using hematoxylin-eosin (HE), alcian blue-periodic acid schiff (AB-PAS), immunofluorescence (IF) staining, and quantitative real-time PCR (qRT-PCR). The components of WTGPD were analyzed using UPLC-Q-TOF-MS. The underlying mechanisms were investigated through network pharmacology, transcriptomics sequencing, western blot (WB), molecular docking, and 16S rRNA sequencing. Results: WTGPD treatment effectively alleviated diarrhea and abnormal pain in IBS-D rats (P P < 0.05). It enhanced the intestinal barrier function by improving colonic structure and increasing the expression of tight junction proteins (P P < 0.05). A total of 155 components were identified in WTGPD. Both network pharmacology and transcriptomics sequencing analysis highlighted MAPK as the key signaling pathway in WTGPD's anti-IBS-D effect. The WB results showed a significant decrease in p-p38, p-ERK and p-JNK expression after WTGPD treatment (P P < 0.0001). Guanosine, adenosine and hesperetin in WTGPD may be involved in regulating the phosphorylation of p38, ERK and JNK. Additionally, WTGPD significantly enhanced microbial diversity and increased the production of colonic valeric acid in IBS-D rats (P P < 0.01). Conclusion: In conclusion, our findings suggest that WTGPD can effectively alleviate IBS-D and improve intestinal barrier likely via inhibiting MAPK signal pathway and improving micobial dysbiosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Influence of probiotic administration on the fecal microbiota in diarrhea-predominant irritable bowel syndrome
    C. Subramanyam
    Nitesh Pratap
    Prasad Gandham
    Rupjyothi Talukdar
    M. Sasikala
    H. V. V. Murthy
    D. Nageshwar Reddy
    Indian Journal of Gastroenterology, 2015, 34 (3) : 275 - 276
  • [42] Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
    Aggarwal, Surbhi
    Ahuja, Vineet
    Paul, Jaishree
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 24 (03) : 422 - 430
  • [43] Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective
    Lewis, James H.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (01) : 13 - 29
  • [44] Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
    Mangel, Allen W.
    Hicks, Gareth A.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2012, 5 : 1 - 10
  • [45] Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome
    Chang, Full-Young
    Lu, Ching-Liang
    Chen, Chih-Yen
    Luo, Jiing-Chyuan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (12) : 2266 - 2272
  • [46] Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome
    Martoni, Christopher J.
    Srivastava, Shalini
    Damholt, Anders
    Leyer, Gregory J.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (28) : 4451 - 4465
  • [47] Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
    Lijun Mei
    Jiaoli Zhou
    Yimo Su
    Kunhong Mao
    Jing Wu
    Caicai Zhu
    Ling He
    Ying Cui
    BMC Gastroenterology, 21
  • [48] Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome
    Munjal, Akhil
    Dedania, Bhavtosh
    Cash, Brooks D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (01) : 63 - 71
  • [49] Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
    Mei, Lijun
    Zhou, Jiaoli
    Su, Yimo
    Mao, Kunhong
    Wu, Jing
    Zhu, Caicai
    He, Ling
    Cui, Ying
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [50] Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
    Katsumata, Ryo
    Shiotani, Akiko
    Murao, Takahisa
    Ishii, Manabu
    Fujita, Minoru
    Matsumoto, Hiroshi
    Haruma, Ken
    INTERNAL MEDICINE, 2017, 56 (09) : 993 - 999